rss
Evid Based Nurs 15:82-83 doi:10.1136/ebnurs-2011-100480
  • Women's health
  • Cohort study

Risk of venous thromboembolism in oral contraceptive users varies according to progestin type

  1. Susan S Jick
  1. Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts, USA
  1. Correspondence to Susan S Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 1 Muzzey Street, Lexington, MA 02421, USA; sjick{at}bu.edu

Commentary on:

Implication for practice and research

  • Combined oral contraceptives (OCs) increase the risk of venous thromboembolism (VTE).

  • The risk of VTE in users of OCs containing desogestrel, gestodene, cyproterone and drospirenone is around twice that of levonorgestrel OCs users.

  • Differences in VTE risk should be taken into consideration when prescribing OCs.

Context

Oral contraceptives first introduced in the 1960s contained high doses of estrogen and progestin. These were associated with increased risk for cardiovascular disease (CVD), including VTE, and high estrogen dose was thought to be responsible.1 In subsequent years, OCs containing lower estrogen doses and different progestins …

No Related Web Pages

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article